• Explore /
  • Poster
  • / Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

Abstract Poster

Authors

Hamid Emamekhoo

Hamid Emamekhoo

University of Wisconsin School of Medicine and Public Health, Madison, WI

Hamid Emamekhoo , Mark Olsen , Bradley Curtis Carthon , Alexandra Drakaki , Ivor John Percent , Ana M. Molina , Daniel C. Cho , Johanna C. Bendell , Lucio N. Gordan , Arash Rezazadeh Kalebasty , Daniel J. George , Thomas E. Hutson , Richard J. Lee , Tina C. Young , Jennifer Johansen , Scott S. Tykodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02982954

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4517)

DOI

10.1200/JCO.2019.37.15_suppl.4517

Abstract #

4517

Poster Bd #

343

Abstract Disclosures

Similar Posters

First Author: Hamid Emamekhoo

First Author: Scott S. Tykodi

First Author: Thomas E. Hutson

First Author: Nizar M. Tannir